| Literature DB >> 21928246 |
Nicola Dipalma1, Vito Luisi, Francesca Di Serio, Antonietta Fontana, Piera Maggiolini, Brunella Licchelli, Ernesto Mera, Lucia Bisceglia, Ida Galise, Michele Loizzi, Maria Annunziata Pizzigallo, Raffaele Molinini, Luigi Vimercati.
Abstract
Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). The aim of this study was to evaluate the role of SMRP in clinic management of MM. We assayed the SMRP concentrations in 354 subjects: 109 healthy volunteers with no history of exposure to asbestos, 26 patients with previous occupational asbestos exposure but who were free from pleural or parenchymal disease, 48 patients with asbestosis, 110 patients with pleural plaques, 25 patients with lung cancer, and 36 patients with MM. We also tested SMRP titers in 2 patients with MM at 5 different times of the disease, to evaluate the trend of the biomarker in the course of therapy. Our data confirm previous experiences with the use of SMRP as a diagnostic marker of MM. Low SMRP levels at diagnosis seem to have a positive prognostic significance.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21928246 DOI： 10.5301/JBM.2011.8614
Source DB: PubMed Journal: Int J Biol Markers ISSN： 0393-6155 Impact factor: 2.659